<DOC>
	<DOCNO>NCT01984047</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability pharmacokinetics GSK3050002 human . Subjects attend clinical unit screen visit eligible consenting , attend participate study within 30 day . Subjects admit clinical unit even prior dose subject receive single intravenous dose GSK3050002 placebo , remain house supervision discharge Day 3 . Subjects return 7 outpatient visit schedule follow 81 day . Finally , follow-up visit 7-14 day follow last visit .</brief_summary>
	<brief_title>Single Dose Escalation Trial Evaluate Safety , Tolerability Pharmacokinetics Pharmacodynamics GSK3050002</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<criteria>Male age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test 12 lead ECG . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion may include Investigator consultation GSK Medical Monitor [ require ] agree document find unlikely introduce additional risk factor interfere study procedure . Body mass index ( BMI ) within range 18 29 kilogram per meter square [ kg/m^2 ] ( inclusive ) . Male subject female partner childbearing potential must agree use one listed contraception method . This criterion must follow 1 month prior first dose study medication 15 week post dose . Capable give write informed consent , include compliance requirement restriction list consent form . Suitable cannulation adequate venous access . Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5xUpper limit Normal [ ULN ] ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single ECG QTcF &lt; 450 millisecond ( msec ) . Criteria Based Upon Medical Histories Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History severe drug allergy include type 1 hypersensitivity reaction parental administration contrast agent , human murine proteins monoclonal antibody . Subject acne require prescription treatment Criteria Based Upon Diagnostic Assessments A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test Human immunodeficiency virus ( HIV ) antibody . Subject heavy smoker define positive smoking breath test &gt; 10 part per million ( ppm ) carbon monoxide ( CO ) . Other Criteria Evidence current risk develop bacterial , fungal , viral infection screen within 7 day dose . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Subject unable refrain take prescription nonprescription drug ( include vitamin dietary herbal supplement ) , within 7 day prior first dose study medication completion followup visit , unless opinion Investigator sponsor medication interfere study . Subject unable abstain travel area carry high risk infection duration study . Exposure four new chemical entity within 12 month prior first dose day . Subject unable abstain vaccinate immunized 4 week prior dose 19 week study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>CCL20</keyword>
	<keyword>safety</keyword>
	<keyword>single dose escalation</keyword>
	<keyword>GSK3050002</keyword>
	<keyword>Phase 1</keyword>
	<keyword>CCR6 receptor</keyword>
</DOC>